To the Editor: Salmonella spp. resistant to multiple antimicrobial agents have emerged worldwide in recent years, but clinical relevance varies with the agent to which resistance evolves. Fluoroquinolones are often the drug of choice to treat gastrointestinal infections in humans, and resistance to this class of antimicrobial agents is associated with increased illness and death (1). Resistance to fluoroquinolones has emerged worldwide during the last decade. Salmonella isolates resistant to oxyiminocephalosporins because they produce extended-spectrum β-lactamases (ESBLs) have emerged worldwide since 1992. This emergence has caused concern since cephalosporins are drugs of choice to treat salmonellosis in children, to whom fluoroquinolones must not be administered because of toxicity issues. In Denmark, the first ESBL-producing isolate of animal origin, Salmonella enterica serovar Virchow isolated from a boar imported from Canada in 2003 was reported (2), but such isolates have not previously been reported in food products. On October 24, recently, S. enterica Virchow with blaCTX-M-9 has also been reported in poultry, poultry products, and humans in France (6), as well as in humans in Spain (7) and the United Kingdom (8). The isolates from France were also resistant to nalidixic acid; the isolates we have obtained from fresh quails imported from France are possibly related to these isolates.

The global food-products trade is expected to increase in the future. Thus, attempts to improve food safety must emphasize detection of antimicrobial drug–resistant bacteria in imported food products. Furthermore, international agreements that limit contamination with drug-resistant bacteria and resistance genes at the primary production site are necessary to ensure consumer safety (9). International agreements must be based on antimicrobial-resistance data and early reports of emerging problems. Recently, the World Health Organization (WHO) launched the Global Salm Surv program (10) to isolate and identify antimicrobial resistance to Salmonella globally.

Many national and international rules, as well as marketing and consumer factors, regulate the interna-
tional trade of food products and live animals. Large international corporations may also affect international trade. For example, McDonald’s Corporation has issued a global policy for antimicrobial drug use in food animals that specifies requirements for their food product suppliers. Local groceries or supermarkets may also impose their own standards nationally. We are aware of only 1 product withdrawal related to antimicrobial resistance, the quail imported from France.

No international standards exist for managing food safety problems related to antimicrobial resistance. However, in 2003 the Food and Agriculture Organization of the United Nations, WHO, and the World Organisation for Animal Health jointly hosted a workshop with a panel of experts to scientifically assess resistance risks related to nonhuman use of antimicrobial drugs (9). The panel’s purpose was also to provide recommendations to the Codex Alimentarius Commission for future risk management of antimicrobial drug resistance (9). Imposing restrictions on products with combinations of resistance, such as simultaneous resistance to quinolones and cephalosporins in Salmonella, as reported in this study, would be a good first step towards managing antimicrobial drug–resistance risks.

Frank M. Aarestrup,* Henrik Hasman,* and Lars Bøge Jensen*
*Danish Institute for Food and Veterinary Research, Copenhagen V, Denmark

References


Address for correspondence: Frank M. Aarestrup, Danish Institute for Food and Veterinary Research, Bülowsvej 27, DK-1790 Copenhagen V, Denmark; fax: 45-72-34-60-01; email: faa@diiF.vdk

Vancomycin-resistant Enterococcus faecium Clone in Swine, Europe

To the Editor: The use of antimicrobial agents for growth promotion (AGP) in food-producing animals has been extensively debated because of the risk of establishing a reservoir of antimicrobial resistance genes or antimicrobial-resistant organisms of potential relevance for human health. This concern has motivated the progressive ban of the use of different AGP in the European Union, which began in 1997 with avoparcin and will end in 2006 (1). Worldwide trade of living animals for food production or breeding and of meat products enables multidrug-resistant pathogens to spread across national borders.

Intercontinental dissemination of antimicrobial-resistant bacteria associated with food animals has been described for particular clones such as Salmonella enterica Typhimurium DT104 or Escherichia coli O157:H7 and for transferable genetic elements such as the genomic island SG1 or the streptococcal plasmid pRE25 (2). Vancomycin-resistant enterococci (VRE) in European farms were initially associated with the intensive use of avoparcin; however, the persistence of VRE in food animal environments after years of avoparcin withdrawal indicates that coselection by further antimicrobial or other agents, increased fitness of strains, and mobile genetic elements cannot be ruled out (1–3).

A specific clone was recently detected among vancomycin-resistant E. faecium (VREF) isolated from different swine farms in Denmark and Switzerland and from a healthy Danish woman without antimicrobial drug exposure who ate pork, chicken, and beef (4,5). Since Portugal and